| 4.94 -1.07 (-17.8%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.57 |
1-year : | 8.77 |
| Resists | First : | 6.48 |
Second : | 7.51 |
| Pivot price | 5.78 |
|||
| Supports | First : | 4.82 |
Second : | 4.01 |
| MAs | MA(5) : | 5.6 |
MA(20) : | 6.04 |
| MA(100) : | 6.07  |
MA(250) : | 4.23 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 23.6 |
D(3) : | 27.5 |
| RSI | RSI(14): 35.2 |
|||
| 52-week | High : | 8.51 | Low : | 2.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IMDX ] has closed above bottom band by 16.5%. Bollinger Bands are 8.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.89 - 5.92 | 5.92 - 5.95 |
| Low: | 4.75 - 4.79 | 4.79 - 4.81 |
| Close: | 4.89 - 4.94 | 4.94 - 4.99 |
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Fri, 27 Feb 2026
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst - Yahoo Finance
Thu, 26 Feb 2026
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement - TipRanks
Tue, 24 Feb 2026
Insight Molecular Diagnostics (IMDX) Price Target Increased by 19.05% to 8.50 - Nasdaq
Mon, 23 Feb 2026
IMDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Wed, 11 Feb 2026
iMDx Announces $26.0 Million Registered Direct Offering - Sahm
Wed, 28 Jan 2026
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$8.13m - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -17 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.868e+007 (%) |
| Held by Institutions | 9.59e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.43e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.22 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 950 % |
| Return on Equity (ttm) | -28.5 % |
| Qtrly Rev. Growth | 603.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.377e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.54 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 225130 |
| Forward Dividend | 163200 |
| Dividend Yield | 4557290% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|